Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 109

1.

WHO working group on the quality, safety and efficacy of japanese encephalitis vaccines (live attenuated) for human use, Bangkok, Thailand, 21-23 February 2012.

Trent DW, Minor P, Jivapaisarnpong T, Shin J; WHO Working Group on the Quality, Safety and Efficacy of Japanese Encephalitis Vaccines Live Attenuated for Human Use.

Biologicals. 2013 Nov;41(6):450-7. doi: 10.1016/j.biologicals.2013.06.001. Epub 2013 Jul 25.

PMID:
23891495
2.

Adaptation of yellow fever virus 17D to Vero cells is associated with mutations in structural and non-structural protein genes.

Beasley DW, Morin M, Lamb AR, Hayman E, Watts DM, Lee CK, Trent DW, Monath TP.

Virus Res. 2013 Sep;176(1-2):280-4. doi: 10.1016/j.virusres.2013.04.003. Epub 2013 Apr 16.

PMID:
23602827
3.

Immune correlates of protection against yellow fever determined by passive immunization and challenge in the hamster model.

Julander JG, Trent DW, Monath TP.

Vaccine. 2011 Aug 11;29(35):6008-16. doi: 10.1016/j.vaccine.2011.06.034. Epub 2011 Jun 28.

4.

An inactivated cell-culture vaccine against yellow fever.

Monath TP, Fowler E, Johnson CT, Balser J, Morin MJ, Sisti M, Trent DW.

N Engl J Med. 2011 Apr 7;364(14):1326-33. doi: 10.1056/NEJMoa1009303.

5.

Inactivated yellow fever 17D vaccine: development and nonclinical safety, immunogenicity and protective activity.

Monath TP, Lee CK, Julander JG, Brown A, Beasley DW, Watts DM, Hayman E, Guertin P, Makowiecki J, Crowell J, Levesque P, Bowick GC, Morin M, Fowler E, Trent DW.

Vaccine. 2010 May 14;28(22):3827-40. doi: 10.1016/j.vaccine.2010.03.023. Epub 2010 Mar 26.

PMID:
20347059
6.

Construction of yellow fever/St. Louis encephalitis chimeric virus and the use of chimeras as a diagnostic tool.

Pugachev KV, Guirakhoo F, Mitchell F, Ocran SW, Parsons M, Johnson BW, Kosoy OL, Lanciotti RS, Roehrig JT, Trent DW, Monath TP.

Am J Trop Med Hyg. 2004 Nov;71(5):639-45.

PMID:
15569798
7.

ChimeriVax-West Nile virus live-attenuated vaccine: preclinical evaluation of safety, immunogenicity, and efficacy.

Arroyo J, Miller C, Catalan J, Myers GA, Ratterree MS, Trent DW, Monath TP.

J Virol. 2004 Nov;78(22):12497-507.

8.

Protection against Japanese encephalitis virus strains representing four genotypes by passive transfer of sera raised against ChimeriVax-JE experimental vaccine.

Beasley DW, Li L, Suderman MT, Guirakhoo F, Trent DW, Monath TP, Shope RE, Barrett AD.

Vaccine. 2004 Sep 9;22(27-28):3722-6.

PMID:
15315852
9.

High fidelity of yellow fever virus RNA polymerase.

Pugachev KV, Guirakhoo F, Ocran SW, Mitchell F, Parsons M, Penal C, Girakhoo S, Pougatcheva SO, Arroyo J, Trent DW, Monath TP.

J Virol. 2004 Jan;78(2):1032-8.

10.

Traditional and novel approaches to flavivirus vaccines.

Pugachev KV, Guirakhoo F, Trent DW, Monath TP.

Int J Parasitol. 2003 May;33(5-6):567-82. Review.

PMID:
12782056
11.

Complete genomic RNA sequence of western equine encephalitis virus and expression of the structural genes.

Netolitzky DJ, Schmaltz FL, Parker MD, Rayner GA, Fisher GR, Trent DW, Bader DE, Nagata LP.

J Gen Virol. 2000 Jan;81(Pt 1):151-9.

PMID:
10640553
12.

Molecular evolution and phylogeny of dengue-4 viruses.

Lanciotti RS, Gubler DJ, Trent DW.

J Gen Virol. 1997 Sep;78 ( Pt 9):2279-84.

PMID:
9292015
14.

Future directions for ensuring viral safety of biopharmaceuticals.

Trent DW.

Dev Biol Stand. 1996;88:333-5. No abstract available.

PMID:
9119159
15.

Nucleotide sequence variation of the envelope protein gene identifies two distinct genotypes of yellow fever virus.

Chang GJ, Cropp BC, Kinney RM, Trent DW, Gubler DJ.

J Virol. 1995 Sep;69(9):5773-80.

16.

Processing of Japanese encephalitis virus non-structural proteins: NS2B-NS3 complex and heterologous proteases.

Jan LR, Yang CS, Trent DW, Falgout B, Lai CJ.

J Gen Virol. 1995 Mar;76 ( Pt 3):573-80.

PMID:
7897348
17.

Molecular basis of attenuation of neurovirulence of wild-type Japanese encephalitis virus strain SA14.

Ni H, Chang GJ, Xie H, Trent DW, Barrett AD.

J Gen Virol. 1995 Feb;76 ( Pt 2):409-13.

PMID:
7844560
18.

Nucleotide sequence analysis of the structural gene coding region of the pestivirus border disease virus.

Sullivan DG, Chang GJ, Trent DW, Akkina RK.

Virus Res. 1994 Sep;33(3):219-28.

PMID:
7985409
19.

A comparison of the nucleotide sequences of eastern and western equine encephalomyelitis viruses with those of other alphaviruses and related RNA viruses.

Weaver SC, Hagenbaugh A, Bellew LA, Netesov SV, Volchkov VE, Chang GJ, Clarke DK, Gousset L, Scott TW, Trent DW, et al.

Virology. 1994 Aug 1;202(2):1083. No abstract available.

PMID:
8030217
20.
21.

Murine T-helper cell immune response to recombinant vaccinia-Venezuelan equine encephalitis virus.

Mathews JH, Kinney RM, Roehrig JT, Barrett AD, Trent DW.

Vaccine. 1994 May;12(7):620-4.

PMID:
8085379
22.
23.

Molecular evolution and epidemiology of dengue-3 viruses.

Lanciotti RS, Lewis JG, Gubler DJ, Trent DW.

J Gen Virol. 1994 Jan;75 ( Pt 1):65-75.

PMID:
8113741
24.

Restriction enzyme analysis of American region dengue viruses.

Vorndam V, Nogueira RM, Trent DW.

Arch Virol. 1994;136(1-2):191-6.

PMID:
7516146
25.

T-helper cell epitopes on the E-glycoprotein of dengue 2 Jamaica virus.

Roehrig JT, Risi PA, Brubaker JR, Hunt AR, Beaty BJ, Trent DW, Mathews JH.

Virology. 1994 Jan;198(1):31-8.

PMID:
7505071
26.

Emergence of epidemic dengue/dengue hemorrhagic fever as a public health problem in the Americas.

Gubler DJ, Trent DW.

Infect Agents Dis. 1993 Dec;2(6):383-93. Review.

PMID:
8012739
27.

Molecular and biological characterization of a non-glycosylated isolate of St Louis encephalitis virus.

Vorndam V, Mathews JH, Barrett AD, Roehrig JT, Trent DW.

J Gen Virol. 1993 Dec;74 ( Pt 12):2653-60.

PMID:
7506301
28.

Phylogenetic relationships of dengue-2 viruses.

Lewis JA, Chang GJ, Lanciotti RS, Kinney RM, Mayer LW, Trent DW.

Virology. 1993 Nov;197(1):216-24.

PMID:
8212556
29.

A comparison of the nucleotide sequences of eastern and western equine encephalomyelitis viruses with those of other alphaviruses and related RNA viruses.

Weaver SC, Hagenbaugh A, Bellew LA, Netesov SV, Volchkov VE, Chang GJ, Clarke DK, Gousset L, Scott TW, Trent DW, et al.

Virology. 1993 Nov;197(1):375-90. Erratum in: Virology. 1994 Aug 1;202(2):1083.

PMID:
8105605
30.
31.

Attenuation of Venezuelan equine encephalitis virus strain TC-83 is encoded by the 5'-noncoding region and the E2 envelope glycoprotein.

Kinney RM, Chang GJ, Tsuchiya KR, Sneider JM, Roehrig JT, Woodward TM, Trent DW.

J Virol. 1993 Mar;67(3):1269-77.

32.

Molecular evidence for the origin of the widespread Venezuelan equine encephalitis epizootic of 1969 to 1972.

Kinney RM, Tsuchiya KR, Sneider JM, Trent DW.

J Gen Virol. 1992 Dec;73 ( Pt 12):3301-5.

PMID:
1469368
33.
34.
35.
36.
37.
38.

Attenuation of wild-type yellow fever virus by passage in HeLa cells.

Barrett AD, Monath TP, Cropp CB, Adkins JA, Ledger TN, Gould EA, Schlesinger JJ, Kinney RM, Trent DW.

J Gen Virol. 1990 Oct;71 ( Pt 10):2301-6.

PMID:
2230735
39.
40.

Variants of Venezuelan equine encephalitis virus that resist neutralization define a domain of the E2 glycoprotein.

Johnson BJ, Brubaker JR, Roehrig JT, Trent DW.

Virology. 1990 Aug;177(2):676-83.

PMID:
1695412
41.

Identification of monoclonal antibodies capable of differentiating antigenic varieties of eastern equine encephalitis viruses.

Roehrig JT, Hunt AR, Chang GJ, Sheik B, Bolin RA, Tsai TF, Trent DW.

Am J Trop Med Hyg. 1990 Apr;42(4):394-8.

PMID:
2158755
42.

Genetic variation and microevolution of dengue 2 virus in Southeast Asia.

Trent DW, Grant JA, Monath TP, Manske CL, Corina M, Fox GE.

Virology. 1989 Oct;172(2):523-35.

PMID:
2529700
43.

Genetic relatedness among structural protein genes of dengue 1 virus strains.

Chu MC, O'Rourke EJ, Trent DW.

J Gen Virol. 1989 Jul;70 ( Pt 7):1701-12.

PMID:
2738579
44.
45.

Recombinant vaccinia virus/Venezuelan equine encephalitis (VEE) virus protects mice from peripheral VEE virus challenge.

Kinney RM, Esposito JJ, Mathews JH, Johnson BJ, Roehrig JT, Barrett AD, Trent DW.

J Virol. 1988 Dec;62(12):4697-702.

46.
47.

Identity of Karelian fever and Ockelbo viruses determined by serum dilution-plaque reduction neutralization tests and oligonucleotide mapping.

Lvov DK, Vladimirtseva EA, Butenko AM, Karabatsos N, Trent DW, Calisher CH.

Am J Trop Med Hyg. 1988 Dec;39(6):607-10.

PMID:
2849885
48.

Recombinant vaccinia/Venezuelan equine encephalitis (VEE) virus expresses VEE structural proteins.

Kinney RM, Esposito JJ, Johnson BJ, Roehrig JT, Mathews JH, Barrett AD, Trent DW.

J Gen Virol. 1988 Dec;69 ( Pt 12):3005-13.

PMID:
2462013
49.

Dengue 2 virus envelope protein expressed by a recombinant vaccinia virus fails to protect monkeys against dengue.

Deubel V, Kinney RM, Esposito JJ, Cropp CB, Vorndam AV, Monath TP, Trent DW.

J Gen Virol. 1988 Aug;69 ( Pt 8):1921-9.

PMID:
3404119

Supplemental Content

Loading ...
Support Center